Cargando…

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

BACKGROUND & AIMS: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology and potential associations between b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sangro, Bruno, Melero, Ignacio, Wadhawan, Samir, Finn, Richard S., Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Boyd, Zachary, Tang, Hao (Tracy), Shen, Yun, Tschaika, Marina, Neely, Jaclyn, El-Khoueiry, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751218/ https://www.ncbi.nlm.nih.gov/pubmed/32710922 http://dx.doi.org/10.1016/j.jhep.2020.07.026

Ejemplares similares

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
por: Sangro, Bruno, et al.
Publicado: (2023)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial
por: Yau, Thomas, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Greten, Tim F, et al.
Publicado: (2021)

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
por: El-Khoueiry, Anthony B., et al.
Publicado: (2022)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
por: Kelley, Robin Kate, et al.
Publicado: (2020)

Treatment options after sorafenib failure in patients with hepatocellular carcinoma
por: Dika, Imane El, et al.
Publicado: (2017)

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Hepatocellular carcinoma, novel therapies on the horizon
por: El Dika, Imane, et al.
Publicado: (2020)

Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa
por: Abou-Alfa, Ghassan
Publicado: (2020)

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
por: Costa, Frederico, et al.
Publicado: (2023)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
por: Kelley, Robin Kate, et al.
Publicado: (2021)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2023)

Hepatocellular Carcinoma in Sub-Saharan Africa
por: Kedar Mukthinuthalapati, V. V. Pavan, et al.
Publicado: (2021)

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
por: de la Torre-Aláez, Manuel, et al.
Publicado: (2022)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
por: Ji, Jun Ho, et al.
Publicado: (2023)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
por: Chami, Perla, et al.
Publicado: (2023)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
por: Lee, Dong Ho, et al.
Publicado: (2021)

Nonsurgical Treatment for Localized Hepatocellular Carcinoma
por: Kennedy, Andrew S., et al.
Publicado: (2014)

Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
por: McQuade, Jennifer L., et al.
Publicado: (2022)

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
por: Carrasquillo, Jorge A., et al.
Publicado: (2018)

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response
por: Bibeau, Kristen, et al.
Publicado: (2022)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective
por: Unfried, Juan Pablo, et al.
Publicado: (2021)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019)

Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
por: Kim, Jaewoong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mhaebnaspk1ajcusilov8073ii